Drugs / VAX128
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01172054 | Jul → Dec 2010 | influenza | VaxInnate Corporation | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VAX128 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01172054 ↗ |
| Modality | Vaccine | “3 novel influenza vaccine constructs” PMID 22796139 ↗ Jul 2012 |
| Route | Intramuscular | “Vaccines were administered IM at doses ranging from 0.5 to 20 μg.” PMID 22796139 ↗ Jul 2012 |